Information and Resources for Investors | Alnylam

% Change:

Volume:

52-Week High:

52-Week Low:

EVENTS & PRESENTATIONS

May 13, 2026

BofA Securities Healthcare Conference

Past Events ›

Apr 30, 2026

Alnylam Pharmaceuticals Q1 2026 Earnings Conference Call

Past Events ›

Mar 24, 2026

Alnylam TTR Investor Webinar

Past Events ›

View all events and presentations ›

2025 Annual Report

2025 Corporate Responsibility Report

capella

Investor & Scientific Presentations

Explore Capella ›

Investor Toolkit

Q1 2026 Earnings Presentation VIEW PDF ›

Latest Form 10-K VIEW PDF ›

Latest Form10-Q VIEW PDF ›

SEC
Filings VIEW All ›

2026 Proxy Statement LEARN MORE ›

View all resources and documents ›

PRESS RELEASES

May 19, 2026

Alnylam Issues 2025 Corporate Responsibility Report

May 12, 2026

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

May 07, 2026

Alnylam to Webcast Presentations at Upcoming Investor Conferences

View all press releases ›